Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) will announce its earnings results before the market opens on Wednesday, August 21st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.
Chemomab Therapeutics Trading Up 10.9 %
Shares of CMMB stock opened at $1.05 on Wednesday. Chemomab Therapeutics has a 12 month low of $0.42 and a 12 month high of $1.58. The company has a market capitalization of $11.60 million, a P/E ratio of -0.66 and a beta of 0.50. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $0.86.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on CMMB shares. Oppenheimer raised Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research report on Monday, May 6th. Maxim Group raised shares of Chemomab Therapeutics to a “strong-buy” rating in a report on Friday, May 24th.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Further Reading
- Five stocks we like better than Chemomab Therapeutics
- What is the Euro STOXX 50 Index?
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- What is a Dividend King?
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.